IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v16y2025i1d10.1038_s41467-025-59615-3.html
   My bibliography  Save this article

Long-Term Efficacy of Pembrolizumab and the Clinical Utility of ctDNA in Locally Advanced dMMR/MSI-H Solid Tumors

Author

Listed:
  • Michael LaPelusa

    (MD Anderson Cancer Center)

  • Wei Qiao

    (MD Anderson Cancer Center)

  • Bryan Iorgulescu

    (MD Anderson Cancer Center)

  • Francis San Lucas

    (MD Anderson Cancer Center)

  • Keyur Patel

    (MD Anderson Cancer Center)

  • Deepak Bhamidipati

    (MD Anderson Cancer Center)

  • Jane Varkey Thomas

    (MD Anderson Cancer Center)

  • Nancy You

    (MD Anderson Cancer Center)

  • Wai Chin Foo

    (MD Anderson Cancer Center)

  • Dipen Maru

    (MD Anderson Cancer Center)

  • Selvi Thirumurthi

    (MD Anderson Cancer Center)

  • Van Morris

    (MD Anderson Cancer Center)

  • Scott Kopetz

    (MD Anderson Cancer Center)

  • Michael Overman

    (MD Anderson Cancer Center)

  • Kaysia Ludford

    (MD Anderson Cancer Center)

Abstract

Neoadjuvant immunotherapy can induce pathologic complete response (pCR) in patients with localized deficient mismatch repair (dMMR)/microsatellite instability-high (MSI-H) tumors. The long-term outcomes of these patients are unknown, as is the clinical utility of measuring circulating tumor DNA (ctDNA). Follow-up was evaluated in patients enrolled in a phase II trial (NCT04082572) that evaluated the efficacy and safety of pembrolizumab in patients with localized dMMR/MSI-H tumors. The primary outcomes of this trial have previously been reported. 3-year EFS and OS rates were 80% (95% CI: 66% – 93%) and 94% (95% CI: 86% – 100%). Patients without detectable ctDNA after pembrolizumab had higher 3-year EFS and OS rates than patients with detectable ctDNA after pembrolizumab (3-year EFS 92% vs 20%; p

Suggested Citation

  • Michael LaPelusa & Wei Qiao & Bryan Iorgulescu & Francis San Lucas & Keyur Patel & Deepak Bhamidipati & Jane Varkey Thomas & Nancy You & Wai Chin Foo & Dipen Maru & Selvi Thirumurthi & Van Morris & Sc, 2025. "Long-Term Efficacy of Pembrolizumab and the Clinical Utility of ctDNA in Locally Advanced dMMR/MSI-H Solid Tumors," Nature Communications, Nature, vol. 16(1), pages 1-6, December.
    • Handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-59615-3
    DOI: 10.1038/s41467-025-59615-3
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-025-59615-3
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-025-59615-3?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-59615-3. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.